News Search Results
May 18, 2026, 08:02 ET Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin®
More news about: Lakewood-Amedex Biotherapeutics Inc.
May 18, 2026, 07:57 ET MS Pharma Announces Strategic Growth Investment from Olayan Financing Company
locally manufactured biologics to the Saudi market. These milestones reinforce the company's commitment to localization under the Saudi National Biotechnology Strategy and Vision 2030. Through the expansion of high-quality biologic therapies across the region and close collaboration with regional and international
More news about: MS Pharma
May 18, 2026, 07:52 ET MS Pharma Announces Strategic Growth Investment from Olayan Financing Company
locally manufactured biologics to the Saudi market. These milestones reinforce the company's commitment to localization under the Saudi National Biotechnology Strategy and Vision 2030. Through the expansion of high-quality biologic therapies across the region and close collaboration with regional and international
More news about: MS Pharma
May 18, 2026, 07:30 ET Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial
WATERTOWN, Mass., May 18, 2026 /PRNewswire/ -- Triveni Bio, Inc., a clinical-stage biotechnology company focused on developing innovative, genetics-informed antibody treatments for inflammatory and immunological (I&I) disorders, today announced
More news about: Triveni Bio
May 18, 2026, 07:01 ET Kali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress
SAN MATEO, Calif., May 18, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting therapies, announced that preclinical data for KT502, its second therapeutic candidate, has
More news about: Kali Therapeutics
May 18, 2026, 07:00 ET Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)
underserved autoimmune and inflammatory diseases."About Earendil Labs: Earendil Labs is an AI-powered biotechnology company advancing next-generation biologics for patients with autoimmune diseases, cancer, and other areas of significant unmet medical need. By
More news about: Earendil Labs
May 18, 2026, 02:54 ET Chandigarh University Biotechnology Scientists Faculty Secure Rs 1.16 Crore Government Grants from ICMR and ANRF for Mustard Yield and Diabetic Kidney Disease Research
faculty and students working in the biotechnology domain under University Centre for Research & Development (UCRD) at Chandigarh University have been making significant strides in the cutting-edge scientific research in areas such as agricultural biotechnology and plant molecular science and healthcare.
More news about: Chandigarh University
May 16, 2026, 11:00 ET Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth
pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 15, 2026, 19:50 ET INVESTOR NOTICE: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Medpace is a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.The Medpace class action lawsuit alleges that defendants throughout the
More news about: Robbins Geller Rudman & Dowd LLP
May 15, 2026, 12:03 ET Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
solutions for the life-science and healthcare sectors. The company partners with most of the top 20 leading pharmaceutical companies and numerous biotechnology firms.Logo - https://mma.prnewswire.com/media/2875012/5972973/Virtual_Science_AI_Logo.jpg
More news about: Virtual Science AI Ltd
May 15, 2026, 11:56 ET Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
solutions for the life-science and healthcare sectors. The company partners with most of the top 20 leading pharmaceutical companies and numerous biotechnology firms.Logo - https://mma.prnewswire.com/media/2875012/5972973/Virtual_Science_AI_Logo.jpg
More news about: Virtual Science AI Ltd
May 15, 2026, 10:25 ET Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
May 15, 2026 /PRNewswire/ -- Atisama Therapeutics (formerly Rage Bio) ("Atisama" or the "Company"), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today reported progress in the Phase
More news about: Atisama Therapeutics
May 15, 2026, 10:03 ET INTERNATIONAL CONSTRUCTION CONSULTANCY ACQUIRES RGD PROJECT MANAGEMENT, EXPANDS ADVANCED TECHNOLOGIES DIVISION
RGD Project Management is an 81‑person firm specializing in technical project management and advisory services for blue‑chip pharmaceutical and biotechnology manufacturers. The firm has delivered more than 2,200 pharmaceutical and high‑technology projects and is widely recognized across North Carolina's
More news about: Cumming Group
May 15, 2026, 10:01 ET Particle Size Analysis Market worth $7.73 billion by 2031 | MarketsandMarkets™
repeatable, and multi-technique measurements within a controlled laboratory setup. These systems are widely adopted across the pharmaceuticals, biotechnology, chemicals, and advanced materials industries, where strict regulatory compliance and detailed particle characterization are essential for product
More news about: MarketsandMarkets
May 15, 2026, 08:20 ET Pulmatrix Announces First Quarter 2026 Financial Results
shareholders. We are pleased to report that on March 26th we announced entering into a merger agreement with Eos SENOLYTIX, a privately held biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases using its proprietary MitoXcel™
More news about: Pulmatrix Inc.
May 15, 2026, 08:05 ET Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
cytokine-targeting strategies, and next-generation therapeutic modalities.The Dermatology Drug Development Summit Europe brings together biotechnology and pharmaceutical companies, translational researchers, clinicians, and industry leaders focused on the future of dermatology therapeutics and
More news about: Scinai Immunotherapeutics Ltd.
May 14, 2026, 21:53 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC
$14 billion. As The Wall Street Journal observed in January 2026, "[f]or context, only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value; the index doesn't include Regencell." At all relevant times, Defendants downplayed the likelihood and severity
More news about: Pomerantz LLP
May 14, 2026, 19:03 ET SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'
SEONGNAM, South Korea, May 14, 2026 /PRNewswire/ -- SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating
More news about: SN BioScience Inc
May 14, 2026, 16:31 ET Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
(CDMO) headquartered in San Antonio,Texas. Velocity Bioworks provides biomanufacturing, process development, and advanced analytics services to biotechnology and biopharmaceutical clients, while also serving as the manufacturing engine for Valion Bio's internal drug development pipeline.About
More news about: Valion Bio, Inc.
May 14, 2026, 16:05 ET MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided
More news about: MetaVia Inc.
May 14, 2026, 14:24 ET IBRX 12-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman
[email protected], Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
May 14, 2026, 13:08 ET Hematology Diagnostics Market Expected to Reach US$ 7.6 Billion by 2030, Growing at 6.4% CAGR: Wissen Research
development expands Sysmex's presence in the haemostasis testing segment of the haematology market in Canada.In May 2025, Shenzhen Dymind Biotechnology Co., Ltd. (China) launched its DH-800 Haematology Analyzer and CA1200 Coagulation Analyzer during an event in Lima, Peru. The launch, held at the
More news about: Wissen Research LLC
May 14, 2026, 11:40 ET Introducing The Nexus Forum: A New Global Biopharma Partnership Summit to Accelerate China-Global Strategic Collaboration
ahead of the ASCO Annual Meeting. This invite-only executive summit will bring together senior leaders from multinational pharmaceutical companies, biotechnology innovators, investors, and cross-border business development teams for high-level partnering, scientific exchange, and strategic collaboration discussions.The
More news about: The Nexus Prelude
May 14, 2026, 10:31 ET Professional Hair Care Market to Reach USD 57.5 billion by 2033, Growing at a CAGR of 5.3% -- Allied Market Research
expansion.The technological frontier encompassing AI-powered diagnostics, microbiome-targeted formulations, waterless concentrates, and biotechnology-derived active ingredients — will fundamentally redefine the professional hair care value proposition. Brands that invest decisively in R&D
More news about: Allied Market Research
May 14, 2026, 10:00 ET Bench International Appoints Mathew Mitchell as Executive Vice President, Business Development
Mitchell will oversee the development of enterprise-level partnerships and advance initiatives supporting the firm's continued expansion across the biotechnology, pharmaceutical, medical technology, and healthcare sectors. With more than two decades of experience in commercial leadership, Mitchell specializes
More news about: Bench International